Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 02/11/2022

    The guardian of the (epi-)genome

    Toxicologists from the University of Konstanz have found that the protein p53 continuously protects our cells from tumorigenesis by coordinating important metabolic processes that stabilize their genomes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/guardian-epi-genome
  • Viral cancer therapy - 26/10/2022 Microscopic image of plaque formation by HSV1 viruses (green fluorescing).

    Therapeutic viruses against tumours and metastases

    Viruses can overcome cell barriers and transfer information to their host cells. They know how to make their host cell’s infrastructure work for them. This makes them excellent biotechnological tools, which a research group from the Fraunhofer IGB in Stuttgart is using to its advantage. The team is developing a therapeutic virus that not only recognises and fights tumours, but also has the potential to reach metastases.

    https://www.gesundheitsindustrie-bw.de/en/article/news/therapeutic-viruses-against-tumours-and-metastases
  • Press release - 17/02/2022

    New organ-on-chip system enables precise monitoring of 3D tumour tissue outside the body

    A research team around Dr. Andreas Weltin, Dr. Jochen Kieninger and Johannes Dornhof from the Department of Microsystems Engineering (IMTEK) at the University of Freiburg has developed a system that, among other things, makes it possible to study the development of tumour cells outside the human body in a three-dimensional environment.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-organ-chip-system-enables-precise-monitoring-3d-tumour-tissue-outside-body
  • Press release - 20/08/2021

    Innovative Drug Discovery

    New drugs are intended to help stop viral zoonoses – infections that jump from animals to humans. To study suitable inhibitors, Prof. Dr Christian Klein from the Institute of Pharmacy and Molecular Biotechnology (IPMB) of Heidelberg University is receiving funding in the amount of 450,000 euros from the Volkswagen Foundation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovative-drug-discovery
  • Gene regulation - 20/07/2021 Vor schwarzem Hintergrund ist ein gelb leuchtendes Chromosom zwischen blau gefärbten Chromosomen sichtbar.

    The many faces of the epigenetic regulator MOF

    Epigenetic modifications play a crucial role in coordinated gene transcription, and are required for a fertilised egg cell to be able to develop into an organism with different cell types. Dr. Asifa Akhtar from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg has been studying the essential epigenetic regulator protein MOF for 20 years.

    https://www.gesundheitsindustrie-bw.de/en/article/news/die-vielen-gesichter-des-epigenetischen-regulators-mof
  • Vaccine development - 25/05/2021 AdobeStock_385688184_CROCOTHERY.jpg

    Vaccines – a beacon of hope in the fight against pandemics

    Having long been considered less lucrative for the big pharmaceutical companies, vaccine development is taking off in an unforeseen way in the wake of the COVID-19 pandemic. Financial support is flooding in and all kinds of vaccine development strategies are being deployed. Among the winners in the competition for effective coronavirus vaccines are vaccines based on RNA technology. The development of much-needed vaccines against many other…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
  • Press release - 21/04/2021

    Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding

    Atriva Therapeutics GmbH, a company that is pioneering the development of therapies for the treatment of viral infections, has secured up to €11.4 million in federal funding. The company, founded in 2015, announced today that it was selected for research funding from the German Federal Ministry of Education and Research (BMBF). Atriva will use the funds to advance its drug ATR-002 towards market maturity as quickly as possible.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-therapeutics-kann-dank-foerdermitteln-covid-19-medikament-schneller-entwickeln
  • Press release - 14/04/2021

    Engineering T cells for cancer therapy efficiently and safely

    Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the German Cancer Research Center (DKFZ) have developed an innovative non-viral vector that can efficiently introduce therapeutic genes into immune cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/engineering-t-cells-cancer-therapy-efficiently-and-safely
  • Press release - 23/03/2021

    CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study

    CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 and a strain of the original SARS-CoV-2 B1 lineage (BavPat1) in a transgenic mouse model.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-covid-19-vaccine-candidate-cvncov-demonstrates-protection-against-sars-cov-2-b1351-variant-south-african-variant-precli
  • Press release - 03/03/2021

    New Baden-Württemberg network to reduce animal experiments

    A new network has been set up in Baden-Württemberg aimed at reducing animal experiments as well as further improving animal welfare. It combines new approaches and measures at the state’s biomedical research locations, which are expected to limit stress in laboratory animals and steadily reduce the number of animals used in research in line with the 3R principles of Replacement, Reduction, and Refinement.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-baden-wuerttemberg-network-reduce-animal-experiments
  • Press release - 23/10/2020

    CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV

    CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced data from preclinical studies of its investigational SARS-CoV-2 vaccine candidate, CVnCoV, in mice and hamsters.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-reports-positive-preclinical-data-its-covid-19-vaccine-candidate-cvncov
  • Atriva Therapeutics - 21/10/2020 Kulturschalen mit blau angefärbten Zellen, zu denen das neue Coronavirus (SARS CoV-2) gegeben wurde. Die mit dem Wirkstoff ATR-002 von Atriva Therapeutics behandelten Zellen (rechte Reihen) zeigen keine weißen Löcher im Zellrasen und somit keine Zellzerstörung.

    COVID-19 pioneer drug in Phase II clinical trial – with double the power

    The effective treatment of people with severe COVID-19 is a major goal during the corona pandemic. ATR-002, an oral small molecule that targets RNA viruses such as influenza virus and SARS-CoV-2, has a dual effect: it impairs viral propagation and also has an immunomodulatory effect. And what’s more, due to its unique cellular mechanism of action, the efficacy of Atrivia Therapeutics’ drug candidate is not reduced by virus mutations and…

    https://www.gesundheitsindustrie-bw.de/en/article/news/covid-19-pioneer-drug-phase-ii-clinical-trial-double-power
  • Press release - 20/10/2020

    EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment

    The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eib-backs-atriva-therapeutics-eur24-million-development-potential-covid-19-treatment
  • Press release - 11/08/2020

    Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan

    Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new German and international investors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-announces-closing-eur-86-million-102-million-oversubscribed-convertible-loan
  • Article - 11/06/2019 ZurHausen.jpg

    New pathogens in beef and cow's milk contributing to the risk of cancer

    A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
  • Press release - 21/09/2017

    Atriva reaches a development milestone and receives an additional tranche of running seed financing to develop its influenza therapeutic to clinical stage

    The next generation of Antiviral Therapies: Co-Led by Stichting Participatie Atriva and High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received a second tranche of its running seed financing in total of € 3 Mn from Dutch, German and Canadian investors, after lead compound ATR-002 (Atriva’s antiviral MEK-Inhibitor against Influenza) has passed an important preclinical milestone paving the way to clinical development stage.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-reaches-a-development-milestone-and-receives-an-additional-tranche-of-running-seed-financing-to-develop-its-influenza-the
  • Article - 15/09/2017 Teaser_ZIKA_Virus_Jarasch.jpg

    Zika virus infections and their consequences

    Infections caused by mosquito-borne Zika viruses during pregnancy can lead to severe brain defects in babies. The European Union has provided funding of around ten million euros for an international research programme on Zika virus infections in which the University Hospital of Heidelberg plays a key role.

    https://www.gesundheitsindustrie-bw.de/en/article/news/zika-virus-infections-and-their-consequences
  • Press release - 07/02/2017

    Atriva receives seed financing to develop its next generation influenza therapeutic

    The next generation of Antiviral Therapies: Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received seed financing from Dutch and German private investors to advance Atriva’s antiviral MEK-Inhibitors (Mitogen-activated protein kinase kinase inhibitor) against Influenza into the clinical development stage.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-receives-seed-financing-to-develop-its-next-generation-influenza-therapeutic
  • Article - 19/07/2016 Symbolic 3D model with a T cell equipped with CAR and the relevant DNA.

    Licence to kill – the enormous potential of CAR T cells

    With 6 million euros of EU funding, the CARAT project aims to optimise a technology called CAR T that is used to equip T cells with antibody fragments and specifically direct them to destroy cancer cells. The CARAT consortium comprises a multinational team of experts from the Institute for Cell- and Gene Therapy at the Freiburg University Medical Center led by Prof. Dr. Toni Cathomen and seven partner institutions. Cathomen’s team is developing…

    https://www.gesundheitsindustrie-bw.de/en/article/news/licence-to-kill-the-enormous-potential-of-car-t-cells
  • Company profile - 27/06/2016 Schematic showing a host cell that is infected by an influenza virus that uses the MEK signalling pathway in the host cells to propagate (left). Several new viruses (red) have been released by the host cell. The schematic on the right-hand side shows the blockage of the signalling pathway. Crossed-out grey virus cells below the host cell indicate that the viruses are no longer able to replicate.

    Atriva Therapeutics GmbH: new ways to treat influenza

    Influenza viruses constantly change and mutate. This makes treatment difficult and vaccination rather touch and go. But what about targeting virus-manipulated cell events rather than using the virus itself as drug target? Atriva Therapeutics GmbH, a start-up company from Tübingen, shows how this works.

    https://www.gesundheitsindustrie-bw.de/en/article/news/atriva-therapeutics-gmbh-new-ways-to-treat-influenza
  • Article - 02/05/2016 Schematic showing immune cells recognise a hepatitis C virus.

    Hepatitis C: a new starting point for vaccine development

    With approximately 150,000 infected people in Germany, hepatitis C is a common disease for which therapies, but no vaccine, are available. Dr. Tobias Böttler from the Freiburg University Medical Center and his team are exploring the body’s immune response to the hepatitis C virus (HCV) and have found valuable information that could be used for vaccine development.

    https://www.gesundheitsindustrie-bw.de/en/article/news/hepatitis-c-a-new-starting-point-for-vaccine-development
  • Vaccine development - 02/11/2015 Valerie_Herrmann.jpg

    A new vaccine could prevent influenza epidemics

    Influenza pandemics are dangerous and can claim many lives. Children and the elderly in particular run a high risk of developing influenza-related complications, because their immune system is often weakened by the virus. In Germany, annual vaccination against seasonal influenza has therefore been recommended for these target groups for quite a few years now. However, producing vaccines is costly and time-consuming. Researchers at the University…

    https://www.gesundheitsindustrie-bw.de/en/article/news/a-new-vaccine-could-prevent-influenza-epidemics
  • Article - 22/06/2015 The schematic shows how the blood vessel-containing printed tissue will look like.

    3D bioprinting: replicating the shape of bone parts

    Prof. Dr. Günter Finkenzeller, head of the Research and Tissue Engineering Laboratory in the Department of Plastic and Hand Surgery at the Freiburg University Medical Centre, and Dr. Peter Koltay from the Department of Microsystems Engineering (IMTEK) at the University of Freiburg, are being given German Research Foundation (DFG) funds for a period of three years to develop a 3D printing technique for functional bone tissue containing blood…

    https://www.gesundheitsindustrie-bw.de/en/article/news/3d-bioprinting-replicating-the-shape-of-bone-parts
  • Article - 18/05/2015 The figures shows a model of a spherical parvovirus. Parvoviruses are non-enveloped viruses, which makes them rather resistant against external influences.

    Parvoviruses can destroy brain tumours

    Parvoviruses such as H-1PV have been shown to selectively attack and destroy human cancer cells. However, they are unable to replicate in healthy human cells. A preliminary clinical trial is currently being carried out to assess the suitability of parvoviruses for treating malignant brain cancer. Scientists from the German Cancer Research Center (DKFZ) have now discovered the cause of the selective effect of H-1PV. The finding helps identify…

    https://www.gesundheitsindustrie-bw.de/en/article/news/parvoviruses-can-destroy-brain-tumours
  • Article - 18/08/2014 Photo of a hand holding a syringe containing a dark fluid towards a naked upper arm.

    The use of human genes as medical products

    In contrast to medications used for treating disease, gene therapy does not use chemical agents to alleviate or cure disease symptoms. Instead, it involves the introduction of a normal copy of a mutated gene to restore the function of a protein. Gene therapy could also be described as a way of restoring the body’s self-healing process. It is an extremely smart idea that enables the sustainable treatment of diseases which cannot usually be…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-use-of-human-genes-as-medical-products

Page 1 / 3

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search